Anavex Life Sciences Corp. (NASDAQ: AVXL) has reported a new publication in the Neurobiology of Aging journal, demonstrating the potential of ANAVEX 3-71 to prevent cognitive decline in Alzheimer's disease. The study shows that ANAVEX 3-71 treatment prevents cognitive impairment, reduces amyloid, and neuroinflammation even after a long drug washout. The drug has already successfully completed a Phase 1 human clinical trial demonstrating good safety and tolerability signals at all doses studied. The company is also on track to release top-line data of ANAVEX 2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.